Becoming the AI Champion of Radiology. Is it time to invest?
RadNet shows how to achieve real productivity gains in cancer early detection and bureaucracy through AI.
I think the stock is ripe for higher prices.
Reading Time: 2 minutes
In medicine, we will see significant advances in the early detection of diseases and the development of new medications thanks to AI. One company that is leading the way in radiology with AI is RadNet. I believe the time is ripe to consider the stock on the long side. Why do I think that? While many corporations are still debating the potential of AI, RadNet is already producing concrete results. The recent acquisition of the French AI specialist Gleamer is far more than just a mere portfolio expansion. It is the crucial catalyst for a productivity...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
